2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163514
    hAChE-IN-8
    hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of hAChE (IC50=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC50=0.542 μM), and does not inhibit Dyrk1A (IC50>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research.
    hAChE-IN-8
  • HY-163519
    α-Synuclein inhibitor 13
    α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research.
    α-Synuclein inhibitor 13
  • HY-163537
    AChE/BuChE-IN-5
    AChE/BuChE-IN-5 (compound 5a) is a dual target inhibitor. AChE/BuChE-IN-5 has excellent nanomolar inhibitory activity on acetylcholinesterase (AChE) (IC50=46.9 nM) and butyryl cholinesterase (BuChE) (IC50=3.5 nM). AChE/BuChE-IN-5 can be used for Alzheimer's Disease research.
    AChE/BuChE-IN-5
  • HY-163543
    Progranulin modulator-2
    Progranulin modulator-2 (compound 18A) is a bromodomain and extra-terminal domain (BET) inhibitor. Progranulin modulator-2 enhances PGRN expression by targeting members of the BET protein family. Progranulin modulator-2 can be used to study the role of BET protein in neurodevelopment, neuroplasticity and neurodegeneration.
    Progranulin modulator-2
  • HY-163562
    JYQ-164
    JYQ-164 is a small molecule inhibitor of Parkinson's disease protein 7 (PARK7/DJ-1) in humans. JYQ-164 works by covalently and selectively targeting Cys106, a key residue of PARK7 (IC50=21 nM). The high inhibitory effect of JYQ-164 on PARK7 is 5 times more potent than the previously reported inhibitor JYQ-88. JYQ-164 can be used in Parkinson's disease and cancer research.
    JYQ-164
  • HY-163564
    JYQ-194
    JYQ-194 is a PROTAC degrader targeting human Parkinson's disease protein 7 (PARK7). JYQ-194 can be used in the study of cancer and neurodegenerative diseases. (Pink: PARK7 ligand (HY-163563); Black: linker (HY-W017440); Blue: E3 ligase ligand (HY-10984)).
    JYQ-194
  • HY-163574
    TDP-43-IN-1 3033951-71-9
    TDP43-IN-1 (example 8) is a TDP43 inhibitor, and can be used for study of neurodegenerative disorders.
    TDP-43-IN-1
  • HY-163575
    TDP-43-IN-2 3033951-93-5
    TDP-43-IN-2 (compound 17) is a TDP-43 inhibitor, and can be used for study of neurodegenerative disease.
    TDP-43-IN-2
  • HY-163613
    NS163
    NS163 is a α-Synuclein aggregation antagonist. NS163 can be used for study of Parkinson’s disease.
    NS163
  • HY-163646
    (Rac)-TZ3O 2218754-19-7
    (Rac)-TZ3O is the (Rac) isomer of TZ3O. TZ3O is an anticholinergic compound with neuroprotective activity. TZ3O improves memory impairment and cognitive decline in a scopolamine-induced Alzheimer's disease rat model and can be used in the study of Alzheimer's disease.
    (Rac)-TZ3O
  • HY-163655
    Glutaminyl Cyclase Inhibitor 6
    Glutaminyl Cyclase Inhibitor 6 (compound BI-43) is a secretory glutaminyl cyclase (sQC) and golgi-resident glutaminyl cyclase (gQC) inhibitor with IC50 values of 0.012 0.040 µM, respectively. Glutaminyl Cyclase Inhibitor 6 has the potential for the research of Parkinson’s disease.
    Glutaminyl Cyclase Inhibitor 6
  • HY-163667
    Atoxifent
    Atoxifent is a potent μ-opioid receptor agonist (EC50=0.39 nM). These receptors are found in brain regions that control pain, emotions, habitual learning, and cognition. Atoxifent exhibits strong analgesic effects and a lower risk of respiratory depression. Atoxifent can be used for research in opioid pharmacology and signal transduction.
    Atoxifent
  • HY-163669
    ITI-333 2117619-00-6
    ITI-333 is a tetracyclic compound with oral bioavailability and analgesic activity, targeting multiple receptors. ITI-333 can be used for research on various forms of pain.
    ITI-333
  • HY-163671
    PW0729 2767348-36-5
    PW0729 (compound 15b) is an orphan GPR52 agonist with potential applications in GPR52 activation, signaling bias, and neuropsychiatric and neurological disorders. The brain exposure characteristics of PW0729 need to be further optimized.
    PW0729
  • HY-163703
    D4R antagonist-2
    D4R antagonist-2 (compound 33) is a D4R antagonist. D4R antagonist-2 has a IC50 value of 210 nM, and a Ki value of 59 nM for D4R. D4R antagonist-2 can be used in the Parkinson's disease research.
    D4R antagonist-2
  • HY-163718
    Ferroptosis-IN-9
    Ferroptosis-IN-9 (compound 23b) is a ferroptosis inhibitor with an IC50 value of >30uM for hERG inhibition. Ferroptosis-IN-9 is a ROS scavenger. Ferroptosis-IN-9 can be used in neurodegenerative disease research.
    Ferroptosis-IN-9
  • HY-163728
    DSP-6745 2235409-96-6
    DSP-6745 is a potent and orally active 5-HT Receptor inhibitor. DSP-6745 can be used in the study of depressive disorder.
    DSP-6745
  • HY-163746
    BuChE-IN-11
    BuChE-IN-11 (Compound 3b-1) is an selective BuChE inhibitor with an IC50 of 0.44 μM for hBuChE. BuChE-IN-11 has high blood-brain barrier permeability and exhibits strong antioxidant activity due to its free radical scavenging properties. BuChE-IN-11 interacts with the choline binding site, acetyl binding site, and peripheral anionic site, exhibiting submicromolar BuChE inhibitory activity and preventing β-amyloid (Aβ) self-aggregation. BuChE-IN-11 holds promise for research in the field of Alzheimer's disease.
    BuChE-IN-11
  • HY-163772
    Fraxinellone analog 1
    Fraxinellone analog 1 (compound 2) is a potent and rapid activator of the Nrf2 mediated antioxidant defense system, which protects against glutamate-mediated excitotoxicity and induces the expression of antioxidant genes Gpx4, Sod1, and Nqo1. Fraxinellone analog 1 has neuroprotective effects and regulatory effects against oxidative stress and inflammation, and can be used in the study of neurodegenerative diseases.
    Fraxinellone analog 1
  • HY-163779
    β-Glucocerebrosidase modulator 1
    β-Glucocerebrosidase modulator 1 (Compound 28) is an allosteric modulator for β-Glucocerebrosidase with an EC50 of 9.0 μM and a Kd of 0.050 μM.
    β-Glucocerebrosidase modulator 1
Cat. No. Product Name / Synonyms Application Reactivity